Jump to section
IdentificationPharmacologyInteractionsReferencesTrialsEconomicsPropertiesSpectraTaxonomySulfadiazine
Identification
- Name
- Sulfadiazine
- Accession Number
- DB00359 (APRD00190)
- Type
- Small Molecule
- Groups
- Approved, Investigational, Vet approved
- Description
One of the short-acting sulfonamides used in combination with pyrimethamine to treat toxoplasmosis in patients with acquired immunodeficiency syndrome and in newborns with congenital infections. [PubChem]
- Structure
Structure for DB00359 (Sulfadiazine)
- Synonyms
- 2-sulfanilamidopyrimidine
- 2-sulfanilylaminopyrimidine
- 4-amino-N-2-pyrimidinylbenzenesulfonamide
- N(1)-2-Pyrimidinylsulfanilamide
- N(1)-2-Pyrimidylsulfanilamide
- N1-2-pyrimidinylsulfanilamide
- N1-2-pyrimidylsulfanilamide
- Sulfadiazina
- Sulfadiazine
- Sulfadiazinum
- Sulfapyrimidine
- Sulphadiazine
- Product Ingredients
Ingredient UNII CAS InChI Key Sulfadiazine sodium 84CS1P306F 547-32-0 JLDCNMJPBBKAHH-UHFFFAOYSA-N - Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Sulfadiazine Tab 7.7gr Tablet 500.5 mg Oral Stanley Pharmaceuticals, A Division Of Vita Health Products Inc. 1957-12-31 2001-07-20 Canada 
- Generic Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Sulfadiazine Tablet 500 mg/1 Oral Remedy Repack 2013-02-11 2016-10-13 US 
Sulfadiazine Tablet 500 mg/1 Oral Eon Labs, Inc. 1994-07-29 Not applicable US - Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Coptin Oral Suspension Sulfadiazine (41 mg) + Trimethoprim (9 mg) Suspension Oral Axcan Pharma 1979-12-31 2006-09-12 Canada Coptin Tab Sulfadiazine (410 mg) + Trimethoprim (90 mg) Tablet Oral Pfizer 1979-12-31 1996-09-09 Canada Coptin Tab Sulfadiazine (410 mg) + Trimethoprim (90 mg) Tablet Oral Axcan Pharma 1979-12-31 2006-09-12 Canada Ovoquinol Cones Sulfadiazine (400 mg) + Diiodohydroxyquinoline (75 mg) + Undecylenic acid (50 mg) Suppository Vaginal Lab Nadeau LtÉe, Division Of Technilab Inc. 1963-12-31 1999-09-28 Canada Ovoquinol Crm Vaginale Sulfadiazine (8 %) + Diiodohydroxyquinoline (2 %) + Undecylenic acid (1 %) Cream Vaginal Lab Nadeau LtÉe, Division Of Technilab Inc. 1980-12-31 1999-09-28 Canada Trisulfaminic Sus Sulfadiazine (167 mg) + Mepyramine maleate (6.25 mg) + Pheniramine maleate (6.25 mg) + Phenylpropanolamine hydrochloride (12.5 mg) + Sulfamerazine (167 mg) + Sulfamethazine (167 mg) Suspension Oral Shepherd Pharmaceuticals Inc. 1959-12-31 2001-04-11 Canada Trisulfaminic Tab Sulfadiazine (167 mg) + Mepyramine maleate (6.25 mg) + Pheniramine maleate (6.25 mg) + Phenylpropanolamine hydrochloride (12.5 mg) + Sulfamerazine (167 mg) + Sulfamethazine (167 mg) Tablet Oral Shepherd Pharmaceuticals Inc. 1959-12-31 2001-04-11 Canada - International/Other Brands
- Adiazine
- Categories
- Amides
- Amines
- Aniline Compounds
- Anti-Bacterial Agents
- Anti-Infective Agents
- Antibacterials for Systemic Use
- Antiinfectives for Systemic Use
- Antiparasitic Agents
- Antiprotozoals
- Blood Glucose Lowering Agents
- Coccidiostats
- Cytochrome P-450 CYP3A Substrates
- Cytochrome P-450 CYP3A4 Substrates
- Cytochrome P-450 CYP3A4 Substrates (strength unknown)
- Cytochrome P-450 Enzyme Inhibitors
- Genito Urinary System and Sex Hormones
- Gynecological Antiinfectives and Antiseptics
- Hypoglycemia-Associated Agents
- Intermediate-Acting Sulfonamides
- Methemoglobinemia Associated Agents
- Sulfanilamides
- Sulfonamide Antibacterial
- Sulfonamides
- Sulfones
- Sulfur Compounds
- UNII
- 0N7609K889
- CAS number
- 68-35-9
- Weight
- Average: 250.277
Monoisotopic: 250.052446274 - Chemical Formula
- C10H10N4O2S
- InChI Key
- SEEPANYCNGTZFQ-UHFFFAOYSA-N
- InChI
- InChI=1S/C10H10N4O2S/c11-8-2-4-9(5-3-8)17(15,16)14-10-12-6-1-7-13-10/h1-7H,11H2,(H,12,13,14)
- IUPAC Name
- 4-amino-N-(pyrimidin-2-yl)benzene-1-sulfonamide
- SMILES
- NC1=CC=C(C=C1)S(=O)(=O)NC1=NC=CC=N1
Pharmacology
- Indication
For the treatment of rheumatic fever and meningococcal meningitis
- Associated Conditions
- Chancroid
- Chlamydial Infections
- Conjunctivitis, Inclusion
- Meningitis caused by Haemophilus influenzae
- Meningococcal Meningitis
- Nocardiosis
- Plague
- Plasmodium Infections
- Toxoplasmosis
- Trachoma
- Urinary Tract Infections (UTIs)
- Wound Sepsis
- Bacterial otitis media caused by Haemophilus influenzae
- Prophylaxis of Rheumatic fever
- Recurrent Rheumatic fever
- Pharmacodynamics
Sulfadiazine is a sulfonamide antibiotic. The sulfonamides are synthetic bacteriostatic antibiotics with a wide spectrum against most gram-positive and many gram-negative organisms. However, many strains of an individual species may be resistant. Sulfonamides inhibit multiplication of bacteria by acting as competitive inhibitors of p-aminobenzoic acid in the folic acid metabolism cycle. Bacterial sensitivity is the same for the various sulfonamides, and resistance to one sulfonamide indicates resistance to all. Most sulfonamides are readily absorbed orally. However, parenteral administration is difficult, since the soluble sulfonamide salts are highly alkaline and irritating to the tissues. The sulfonamides are widely distributed throughout all tissues. High levels are achieved in pleural, peritoneal, synovial, and ocular fluids. Although these drugs are no longer used to treat meningitis, CSF levels are high in meningeal infections. Their antibacterial action is inhibited by pus.
- Mechanism of action
Sulfadiazine is a competitive inhibitor of the bacterial enzyme dihydropteroate synthetase. This enzyme is needed for the proper processing of para-aminobenzoic acid (PABA) which is essential for folic acid synthesis. The inhibited reaction is necessary in these organisms for the synthesis of folic acid.
Target Actions Organism ADihydropteroate synthetase inhibitorPlasmodium falciparum - Absorption
- Not Available
- Volume of distribution
- Not Available
- Protein binding
- Not Available
- Metabolism
- Not Available
- Route of elimination
Sulfadiazine is excreted largely in the urine.
- Half life
- Not Available
- Clearance
- Not Available
- Toxicity
Oral LD50 in mouse is 1500 mg/kg.
- Affected organisms
- Enteric bacteria and other eubacteria
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
Drug Interaction Drug group (1S,6R)-3-{[3-(TRIFLUOROMETHYL)-5,6-DIHYDRO[1,2,4]TRIAZOLO[4,3-A]PYRAZIN-7(8H)-YL]CARBONYL}-6-(2,4,5-TRIFLUOROPHENYL)CYCLOHEX-3-EN-1-AMINE (1S,6R)-3-{[3-(TRIFLUOROMETHYL)-5,6-DIHYDRO[1,2,4]TRIAZOLO[4,3-A]PYRAZIN-7(8H)-YL]CARBONYL}-6-(2,4,5-TRIFLUOROPHENYL)CYCLOHEX-3-EN-1-AMINE may increase the hypoglycemic activities of Sulfadiazine. Experimental 2,4-thiazolidinedione 2,4-thiazolidinedione may increase the hypoglycemic activities of Sulfadiazine. Investigational 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypoglycemic activities of Sulfadiazine. Experimental Abiraterone The serum concentration of Sulfadiazine can be increased when it is combined with Abiraterone. Approved Acarbose The therapeutic efficacy of Acarbose can be increased when used in combination with Sulfadiazine. Approved, Investigational Aceclofenac The metabolism of Aceclofenac can be decreased when combined with Sulfadiazine. Approved, Investigational Acenocoumarol The metabolism of Acenocoumarol can be decreased when combined with Sulfadiazine. Approved, Investigational Acetohexamide Acetohexamide may increase the hypoglycemic activities of Sulfadiazine. Approved, Investigational, Withdrawn Acetyl sulfisoxazole The metabolism of Acetyl sulfisoxazole can be decreased when combined with Sulfadiazine. Approved, Vet Approved Acetylsalicylic acid The metabolism of Acetylsalicylic acid can be decreased when combined with Sulfadiazine. Approved, Vet Approved AICA ribonucleotide AICA ribonucleotide may increase the hypoglycemic activities of Sulfadiazine. Experimental, Investigational Alaproclate Alaproclate may increase the hypoglycemic activities of Sulfadiazine. Experimental Allicin Allicin may increase the hypoglycemic activities of Sulfadiazine. Investigational Alogliptin Alogliptin may increase the hypoglycemic activities of Sulfadiazine. Approved Alosetron The metabolism of Alosetron can be decreased when combined with Sulfadiazine. Approved, Withdrawn Aloxiprin Aloxiprin may increase the hypoglycemic activities of Sulfadiazine. Experimental Alprazolam The metabolism of Alprazolam can be decreased when combined with Sulfadiazine. Approved, Illicit, Investigational Aminophenazone The metabolism of Aminophenazone can be decreased when combined with Sulfadiazine. Approved, Withdrawn Aminosalicylic Acid Aminosalicylic Acid may increase the hypoglycemic activities of Sulfadiazine. Approved Amiodarone The metabolism of Sulfadiazine can be decreased when combined with Amiodarone. Approved, Investigational Amitriptyline The metabolism of Amitriptyline can be decreased when combined with Sulfadiazine. Approved Amphetamine Amphetamine may increase the hypoglycemic activities of Sulfadiazine. Approved, Illicit, Investigational Amprenavir The metabolism of Amprenavir can be decreased when combined with Sulfadiazine. Approved, Investigational Antipyrine The metabolism of Antipyrine can be decreased when combined with Sulfadiazine. Approved, Investigational Apalutamide The serum concentration of Sulfadiazine can be decreased when it is combined with Apalutamide. Approved, Investigational Apixaban The metabolism of Apixaban can be decreased when combined with Sulfadiazine. Approved Aprepitant The serum concentration of Sulfadiazine can be increased when it is combined with Aprepitant. Approved, Investigational Arachidonic Acid The metabolism of Arachidonic Acid can be decreased when combined with Sulfadiazine. Experimental Arformoterol The metabolism of Arformoterol can be decreased when combined with Sulfadiazine. Approved, Investigational Artemether The metabolism of Artemether can be decreased when combined with Sulfadiazine. Approved Asunaprevir The metabolism of Asunaprevir can be decreased when combined with Sulfadiazine. Approved, Investigational, Withdrawn Atazanavir The metabolism of Sulfadiazine can be decreased when combined with Atazanavir. Approved, Investigational Atomoxetine The metabolism of Sulfadiazine can be decreased when combined with Atomoxetine. Approved Avatrombopag The metabolism of Avatrombopag can be decreased when combined with Sulfadiazine. Approved, Investigational Azelastine The metabolism of Azelastine can be decreased when combined with Sulfadiazine. Approved Balaglitazone Balaglitazone may increase the hypoglycemic activities of Sulfadiazine. Investigational Balsalazide Balsalazide may increase the hypoglycemic activities of Sulfadiazine. Approved, Investigational Bempedoic acid Bempedoic acid may increase the hypoglycemic activities of Sulfadiazine. Investigational Benmoxin Benmoxin may increase the hypoglycemic activities of Sulfadiazine. Withdrawn Bexarotene The metabolism of Bexarotene can be decreased when combined with Sulfadiazine. Approved, Investigational Boceprevir The metabolism of Sulfadiazine can be decreased when combined with Boceprevir. Approved, Withdrawn Bortezomib The metabolism of Bortezomib can be decreased when combined with Sulfadiazine. Approved, Investigational Bosentan The serum concentration of Bosentan can be increased when it is combined with Sulfadiazine. Approved, Investigational Brivaracetam The metabolism of Brivaracetam can be decreased when combined with Sulfadiazine. Approved, Investigational Brofaromine Brofaromine may increase the hypoglycemic activities of Sulfadiazine. Experimental Buformin Buformin may increase the hypoglycemic activities of Sulfadiazine. Investigational, Withdrawn Buprenorphine The metabolism of Buprenorphine can be decreased when combined with Sulfadiazine. Approved, Illicit, Investigational, Vet Approved Cabozantinib The metabolism of Cabozantinib can be decreased when combined with Sulfadiazine. Approved, Investigational Canagliflozin Canagliflozin may increase the hypoglycemic activities of Sulfadiazine. Approved Candesartan The metabolism of Candesartan can be decreased when combined with Sulfadiazine. Experimental Candesartan cilexetil The metabolism of Candesartan cilexetil can be decreased when combined with Sulfadiazine. Approved Cannabidiol The metabolism of Cannabidiol can be decreased when combined with Sulfadiazine. Approved, Investigational Capecitabine The metabolism of Sulfadiazine can be decreased when combined with Capecitabine. Approved, Investigational Carbamazepine The metabolism of Sulfadiazine can be increased when combined with Carbamazepine. Approved, Investigational Carbaspirin calcium Carbaspirin calcium may increase the hypoglycemic activities of Sulfadiazine. Experimental, Investigational Carbinoxamine The metabolism of Carbinoxamine can be decreased when combined with Sulfadiazine. Approved Carbutamide Carbutamide may increase the hypoglycemic activities of Sulfadiazine. Experimental Caroxazone Caroxazone may increase the hypoglycemic activities of Sulfadiazine. Withdrawn Castanospermine Castanospermine may increase the hypoglycemic activities of Sulfadiazine. Experimental Celecoxib The metabolism of Celecoxib can be decreased when combined with Sulfadiazine. Approved, Investigational Ceritinib The serum concentration of Sulfadiazine can be increased when it is combined with Ceritinib. Approved Chlorpropamide The metabolism of Chlorpropamide can be decreased when combined with Sulfadiazine. Approved, Investigational Cholecalciferol The metabolism of Sulfadiazine can be decreased when combined with Cholecalciferol. Approved, Nutraceutical Ciglitazone Ciglitazone may increase the hypoglycemic activities of Sulfadiazine. Experimental Cinoxacin Cinoxacin may increase the hypoglycemic activities of Sulfadiazine. Approved, Investigational, Withdrawn Ciprofloxacin The therapeutic efficacy of Sulfadiazine can be increased when used in combination with Ciprofloxacin. Approved, Investigational Cisapride The metabolism of Cisapride can be decreased when combined with Sulfadiazine. Approved, Investigational, Withdrawn Citalopram Citalopram may increase the hypoglycemic activities of Sulfadiazine. Approved Clarithromycin The metabolism of Sulfadiazine can be decreased when combined with Clarithromycin. Approved Clopidogrel The metabolism of Clopidogrel can be decreased when combined with Sulfadiazine. Approved Clorindione Sulfadiazine may increase the anticoagulant activities of Clorindione. Experimental Clotrimazole The metabolism of Sulfadiazine can be decreased when combined with Clotrimazole. Approved, Vet Approved Clozapine The metabolism of Clozapine can be decreased when combined with Sulfadiazine. Approved Cobicistat The metabolism of Sulfadiazine can be decreased when combined with Cobicistat. Approved Conivaptan The serum concentration of Conivaptan can be increased when it is combined with Sulfadiazine. Approved, Investigational Crisaborole The metabolism of Sulfadiazine can be decreased when combined with Crisaborole. Approved, Investigational Crizotinib The metabolism of Sulfadiazine can be decreased when combined with Crizotinib. Approved Curcumin The metabolism of Sulfadiazine can be decreased when combined with Curcumin. Approved, Investigational Cyclobenzaprine Cyclobenzaprine may decrease the hypoglycemic activities of Sulfadiazine. Approved Cyclophosphamide The metabolism of Cyclophosphamide can be decreased when combined with Sulfadiazine. Approved, Investigational Cyclosporine The metabolism of Cyclosporine can be increased when combined with Sulfadiazine. Approved, Investigational, Vet Approved Cyproterone acetate The serum concentration of Sulfadiazine can be decreased when it is combined with Cyproterone acetate. Approved, Investigational Dabrafenib The serum concentration of Sulfadiazine can be decreased when it is combined with Dabrafenib. Approved, Investigational Dapagliflozin The therapeutic efficacy of Dapagliflozin can be increased when used in combination with Sulfadiazine. Approved Dapoxetine Dapoxetine may increase the hypoglycemic activities of Sulfadiazine. Investigational Dapsone The risk or severity of adverse effects can be increased when Dapsone is combined with Sulfadiazine. Approved, Investigational Darunavir The metabolism of Sulfadiazine can be decreased when combined with Darunavir. Approved Dasatinib The serum concentration of Sulfadiazine can be increased when it is combined with Dasatinib. Approved, Investigational Deferasirox The serum concentration of Sulfadiazine can be decreased when it is combined with Deferasirox. Approved, Investigational Delavirdine The metabolism of Sulfadiazine can be decreased when combined with Delavirdine. Approved Deoxyspergualin Deoxyspergualin may increase the hypoglycemic activities of Sulfadiazine. Investigational Dersalazine Dersalazine may increase the hypoglycemic activities of Sulfadiazine. Investigational Desvenlafaxine Desvenlafaxine may increase the hypoglycemic activities of Sulfadiazine. Approved, Investigational Dexamethasone The therapeutic efficacy of Sulfadiazine can be decreased when used in combination with Dexamethasone. Approved, Investigational, Vet Approved Dexketoprofen The risk or severity of adverse effects can be increased when Dexketoprofen is combined with Sulfadiazine. Approved, Investigational Diazepam The metabolism of Diazepam can be decreased when combined with Sulfadiazine. Approved, Illicit, Investigational, Vet Approved Dicoumarol The metabolism of Dicoumarol can be decreased when combined with Sulfadiazine. Approved Diflunisal Diflunisal may increase the hypoglycemic activities of Sulfadiazine. Approved, Investigational Dihydroergotamine The metabolism of Sulfadiazine can be decreased when combined with Dihydroergotamine. Approved, Investigational Diltiazem The metabolism of Sulfadiazine can be decreased when combined with Diltiazem. Approved, Investigational Diphenadione Sulfadiazine may increase the anticoagulant activities of Diphenadione. Experimental Disopyramide Disopyramide may increase the hypoglycemic activities of Sulfadiazine. Approved Doconexent The metabolism of Doconexent can be decreased when combined with Sulfadiazine. Approved, Investigational Dolasetron The metabolism of Dolasetron can be decreased when combined with Sulfadiazine. Approved, Investigational Donepezil The metabolism of Donepezil can be decreased when combined with Sulfadiazine. Approved Dopamine The metabolism of Dopamine can be decreased when combined with Sulfadiazine. Approved Dorzolamide The metabolism of Dorzolamide can be decreased when combined with Sulfadiazine. Approved Dosulepin The metabolism of Sulfadiazine can be decreased when combined with Dosulepin. Approved Doxepin The metabolism of Doxepin can be decreased when combined with Sulfadiazine. Approved, Investigational Doxycycline The metabolism of Sulfadiazine can be decreased when combined with Doxycycline. Approved, Investigational, Vet Approved Dronabinol The serum concentration of Dronabinol can be increased when it is combined with Sulfadiazine. Approved, Illicit Dronedarone The metabolism of Sulfadiazine can be decreased when combined with Dronedarone. Approved Dulaglutide Dulaglutide may increase the hypoglycemic activities of Sulfadiazine. Approved, Investigational Duloxetine Duloxetine may increase the hypoglycemic activities of Sulfadiazine. Approved Efavirenz The metabolism of Sulfadiazine can be decreased when combined with Efavirenz. Approved, Investigational Eletriptan The metabolism of Eletriptan can be decreased when combined with Sulfadiazine. Approved, Investigational Empagliflozin Empagliflozin may increase the hypoglycemic activities of Sulfadiazine. Approved Enasidenib The metabolism of Enasidenib can be decreased when combined with Sulfadiazine. Approved, Investigational Englitazone Englitazone may increase the hypoglycemic activities of Sulfadiazine. Experimental Enoxacin Enoxacin may increase the hypoglycemic activities of Sulfadiazine. Approved, Investigational Enzalutamide The serum concentration of Sulfadiazine can be decreased when it is combined with Enzalutamide. Approved Epoprostenol The metabolism of Epoprostenol can be decreased when combined with Sulfadiazine. Approved Erythromycin The metabolism of Sulfadiazine can be decreased when combined with Erythromycin. Approved, Investigational, Vet Approved Escitalopram Escitalopram may increase the hypoglycemic activities of Sulfadiazine. Approved, Investigational Estradiol The therapeutic efficacy of Sulfadiazine can be decreased when used in combination with Estradiol. Approved, Investigational, Vet Approved Estradiol acetate The metabolism of Estradiol acetate can be decreased when combined with Sulfadiazine. Approved, Investigational, Vet Approved Estradiol benzoate The metabolism of Estradiol benzoate can be decreased when combined with Sulfadiazine. Approved, Investigational, Vet Approved Estradiol cypionate The metabolism of Estradiol cypionate can be decreased when combined with Sulfadiazine. Approved, Investigational, Vet Approved Estradiol dienanthate The metabolism of Estradiol dienanthate can be decreased when combined with Sulfadiazine. Approved, Investigational, Vet Approved Estradiol valerate The metabolism of Estradiol valerate can be decreased when combined with Sulfadiazine. Approved, Investigational, Vet Approved Estrone The metabolism of Estrone can be decreased when combined with Sulfadiazine. Approved Eszopiclone The metabolism of Eszopiclone can be decreased when combined with Sulfadiazine. Approved, Investigational Ethinyl Estradiol The therapeutic efficacy of Sulfadiazine can be decreased when used in combination with Ethinyl Estradiol. Approved Ethyl biscoumacetate Sulfadiazine may increase the anticoagulant activities of Ethyl biscoumacetate. Withdrawn Etodolac The metabolism of Etodolac can be decreased when combined with Sulfadiazine. Approved, Investigational, Vet Approved Etoperidone Etoperidone may increase the hypoglycemic activities of Sulfadiazine. Withdrawn Etoricoxib The metabolism of Etoricoxib can be decreased when combined with Sulfadiazine. Approved, Investigational Etravirine The metabolism of Etravirine can be decreased when combined with Sulfadiazine. Approved Everolimus The therapeutic efficacy of Sulfadiazine can be decreased when used in combination with Everolimus. Approved Exenatide Exenatide may increase the hypoglycemic activities of Sulfadiazine. Approved, Investigational Fleroxacin Fleroxacin may increase the hypoglycemic activities of Sulfadiazine. Approved Floxuridine The metabolism of Sulfadiazine can be decreased when combined with Floxuridine. Approved Fluconazole The metabolism of Sulfadiazine can be decreased when combined with Fluconazole. Approved, Investigational Fluindione Sulfadiazine may increase the anticoagulant activities of Fluindione. Approved, Investigational Flumequine Flumequine may increase the hypoglycemic activities of Sulfadiazine. Withdrawn Flunitrazepam The metabolism of Flunitrazepam can be decreased when combined with Sulfadiazine. Approved, Illicit Fluorouracil The metabolism of Sulfadiazine can be decreased when combined with Fluorouracil. Approved Fluoxetine Fluoxetine may increase the hypoglycemic activities of Sulfadiazine. Approved, Vet Approved Fluoxymesterone Fluoxymesterone may increase the hypoglycemic activities of Sulfadiazine. Approved, Illicit Flurbiprofen The metabolism of Flurbiprofen can be decreased when combined with Sulfadiazine. Approved, Investigational Fluvoxamine Fluvoxamine may increase the hypoglycemic activities of Sulfadiazine. Approved, Investigational Formoterol The metabolism of Formoterol can be decreased when combined with Sulfadiazine. Approved, Investigational Fosamprenavir The metabolism of Sulfadiazine can be decreased when combined with Fosamprenavir. Approved Fosaprepitant The serum concentration of Sulfadiazine can be increased when it is combined with Fosaprepitant. Approved Fosphenytoin The metabolism of Sulfadiazine can be increased when combined with Fosphenytoin. Approved, Investigational Furazolidone Furazolidone may increase the hypoglycemic activities of Sulfadiazine. Approved, Investigational, Vet Approved Furosemide The therapeutic efficacy of Sulfadiazine can be increased when used in combination with Furosemide. Approved, Vet Approved Fusidic Acid The serum concentration of Sulfadiazine can be increased when it is combined with Fusidic Acid. Approved, Investigational Garenoxacin Garenoxacin may increase the hypoglycemic activities of Sulfadiazine. Investigational Gatifloxacin Gatifloxacin may increase the hypoglycemic activities of Sulfadiazine. Approved, Investigational Gavestinel The metabolism of Gavestinel can be decreased when combined with Sulfadiazine. Investigational Gemfibrozil The metabolism of Sulfadiazine can be decreased when combined with Gemfibrozil. Approved Gemifloxacin Gemifloxacin may increase the hypoglycemic activities of Sulfadiazine. Approved, Investigational Glibornuride Glibornuride may increase the hypoglycemic activities of Sulfadiazine. Investigational, Withdrawn Gliclazide The metabolism of Gliclazide can be decreased when combined with Sulfadiazine. Approved Glimepiride The therapeutic efficacy of Glimepiride can be increased when used in combination with Sulfadiazine. Approved Glipizide The therapeutic efficacy of Glipizide can be increased when used in combination with Sulfadiazine. Approved, Investigational Gliquidone Gliquidone may increase the hypoglycemic activities of Sulfadiazine. Approved, Investigational Glisoxepide Sulfadiazine may increase the hypoglycemic activities of Glisoxepide. Investigational GLPG-0492 GLPG-0492 may increase the hypoglycemic activities of Sulfadiazine. Investigational Glyburide The therapeutic efficacy of Glyburide can be increased when used in combination with Sulfadiazine. Approved Grepafloxacin Grepafloxacin may increase the hypoglycemic activities of Sulfadiazine. Approved, Investigational, Withdrawn Guacetisal Guacetisal may increase the hypoglycemic activities of Sulfadiazine. Experimental Gusperimus Gusperimus may increase the hypoglycemic activities of Sulfadiazine. Investigational Haloperidol The metabolism of Haloperidol can be decreased when combined with Sulfadiazine. Approved Halothane The metabolism of Halothane can be decreased when combined with Sulfadiazine. Approved, Vet Approved Harmaline Harmaline may increase the hypoglycemic activities of Sulfadiazine. Experimental Hemoglobin crosfumaril Hemoglobin crosfumaril may increase the hypoglycemic activities of Sulfadiazine. Experimental Hexobarbital The metabolism of Hexobarbital can be decreased when combined with Sulfadiazine. Approved Hydracarbazine Hydracarbazine may increase the hypoglycemic activities of Sulfadiazine. Experimental Hydrochlorothiazide The therapeutic efficacy of Sulfadiazine can be decreased when used in combination with Hydrochlorothiazide. Approved, Vet Approved Hydrocortisone The therapeutic efficacy of Sulfadiazine can be decreased when used in combination with Hydrocortisone. Approved, Vet Approved Hydromorphone The metabolism of Hydromorphone can be decreased when combined with Sulfadiazine. Approved, Illicit Idarubicin The metabolism of Idarubicin can be decreased when combined with Sulfadiazine. Approved Idelalisib The metabolism of Sulfadiazine can be decreased when combined with Idelalisib. Approved Ifosfamide The metabolism of Ifosfamide can be decreased when combined with Sulfadiazine. Approved Imatinib The metabolism of Imatinib can be decreased when combined with Sulfadiazine. Approved Indalpine Indalpine may increase the hypoglycemic activities of Sulfadiazine. Investigational, Withdrawn Indinavir The metabolism of Sulfadiazine can be decreased when combined with Indinavir. Approved Indisulam The metabolism of Indisulam can be decreased when combined with Sulfadiazine. Investigational Indomethacin The metabolism of Indomethacin can be decreased when combined with Sulfadiazine. Approved, Investigational Insulin Aspart Sulfadiazine may increase the hypoglycemic activities of Insulin Aspart. Approved Insulin Detemir Sulfadiazine may increase the hypoglycemic activities of Insulin Detemir. Approved Insulin Glargine Insulin Glargine may increase the hypoglycemic activities of Sulfadiazine. Approved Insulin Glulisine Sulfadiazine may increase the hypoglycemic activities of Insulin Glulisine. Approved Insulin Human Insulin Human may increase the hypoglycemic activities of Sulfadiazine. Approved, Investigational Insulin Lispro Insulin Lispro may increase the hypoglycemic activities of Sulfadiazine. Approved Insulin Pork Insulin Pork may increase the hypoglycemic activities of Sulfadiazine. Approved Iproclozide Iproclozide may increase the hypoglycemic activities of Sulfadiazine. Withdrawn Iproniazid Iproniazid may increase the hypoglycemic activities of Sulfadiazine. Withdrawn Irbesartan The metabolism of Irbesartan can be decreased when combined with Sulfadiazine. Approved, Investigational Isavuconazole The serum concentration of Sulfadiazine can be increased when it is combined with Isavuconazole. Approved, Investigational Isavuconazonium The metabolism of Sulfadiazine can be decreased when combined with Isavuconazonium. Approved, Investigational Isocarboxazid Isocarboxazid may increase the hypoglycemic activities of Sulfadiazine. Approved Isoniazid The metabolism of Sulfadiazine can be decreased when combined with Isoniazid. Approved, Investigational Itraconazole The metabolism of Sulfadiazine can be decreased when combined with Itraconazole. Approved, Investigational Ivacaftor The serum concentration of Sulfadiazine can be increased when it is combined with Ivacaftor. Approved Ixazomib The metabolism of Ixazomib can be decreased when combined with Sulfadiazine. Approved, Investigational Ketamine The metabolism of Ketamine can be decreased when combined with Sulfadiazine. Approved, Vet Approved Ketobemidone The metabolism of Ketobemidone can be decreased when combined with Sulfadiazine. Approved, Investigational Ketoconazole The metabolism of Sulfadiazine can be decreased when combined with Ketoconazole. Approved, Investigational Ketoprofen The metabolism of Ketoprofen can be decreased when combined with Sulfadiazine. Approved, Vet Approved Lacosamide The serum concentration of Lacosamide can be increased when it is combined with Sulfadiazine. Approved Lanreotide Sulfadiazine may increase the hypoglycemic activities of Lanreotide. Approved Lansoprazole The metabolism of Lansoprazole can be decreased when combined with Sulfadiazine. Approved, Investigational Lapatinib The metabolism of Sulfadiazine can be decreased when combined with Lapatinib. Approved, Investigational Leflunomide The metabolism of Leflunomide can be decreased when combined with Sulfadiazine. Approved, Investigational Lesinurad The metabolism of Lesinurad can be decreased when combined with Sulfadiazine. Approved, Investigational Levofloxacin Levofloxacin may increase the hypoglycemic activities of Sulfadiazine. Approved, Investigational Levomilnacipran Levomilnacipran may increase the hypoglycemic activities of Sulfadiazine. Approved, Investigational Levonorgestrel The therapeutic efficacy of Sulfadiazine can be decreased when used in combination with Levonorgestrel. Approved, Investigational Licofelone The metabolism of Licofelone can be decreased when combined with Sulfadiazine. Investigational Linagliptin Linagliptin may increase the hypoglycemic activities of Sulfadiazine. Approved Liraglutide Liraglutide may increase the hypoglycemic activities of Sulfadiazine. Approved Lobeglitazone The metabolism of Sulfadiazine can be decreased when combined with Lobeglitazone. Approved, Investigational Lomefloxacin Lomefloxacin may increase the hypoglycemic activities of Sulfadiazine. Approved, Investigational Lopinavir The metabolism of Sulfadiazine can be decreased when combined with Lopinavir. Approved Lornoxicam The metabolism of Lornoxicam can be decreased when combined with Sulfadiazine. Approved, Investigational Lorpiprazole The serum concentration of Sulfadiazine can be increased when it is combined with Lorpiprazole. Approved Lovastatin The metabolism of Sulfadiazine can be decreased when combined with Lovastatin. Approved, Investigational Luliconazole The serum concentration of Sulfadiazine can be increased when it is combined with Luliconazole. Approved Lumacaftor The serum concentration of Sulfadiazine can be increased when it is combined with Lumacaftor. Approved Lumiracoxib The metabolism of Lumiracoxib can be decreased when combined with Sulfadiazine. Approved, Investigational Mebanazine Mebanazine may increase the hypoglycemic activities of Sulfadiazine. Withdrawn Mecamylamine The risk or severity of adverse effects can be increased when Sulfadiazine is combined with Mecamylamine. Approved, Investigational Mecasermin Sulfadiazine may increase the hypoglycemic activities of Mecasermin. Approved, Investigational Medical Cannabis The metabolism of Medical Cannabis can be decreased when combined with Sulfadiazine. Experimental, Investigational Mefenamic acid The metabolism of Mefenamic acid can be decreased when combined with Sulfadiazine. Approved Melatonin The metabolism of Melatonin can be decreased when combined with Sulfadiazine. Approved, Nutraceutical, Vet Approved Meloxicam The metabolism of Meloxicam can be decreased when combined with Sulfadiazine. Approved, Vet Approved Mephenytoin The metabolism of Mephenytoin can be decreased when combined with Sulfadiazine. Investigational, Withdrawn Mesalazine Mesalazine may increase the hypoglycemic activities of Sulfadiazine. Approved Mesterolone Mesterolone may increase the hypoglycemic activities of Sulfadiazine. Experimental Mestranol The metabolism of Mestranol can be decreased when combined with Sulfadiazine. Approved Metahexamide Sulfadiazine may increase the hypoglycemic activities of Metahexamide. Experimental Metformin The therapeutic efficacy of Metformin can be increased when used in combination with Sulfadiazine. Approved Methadone The metabolism of Methadone can be decreased when combined with Sulfadiazine. Approved Methenamine The risk or severity of adverse effects can be increased when Methenamine is combined with Sulfadiazine. Approved, Vet Approved Methotrexate The risk or severity of adverse effects can be increased when Sulfadiazine is combined with Methotrexate. Approved Methoxyflurane The metabolism of Methoxyflurane can be decreased when combined with Sulfadiazine. Approved, Investigational, Vet Approved Methyl salicylate Methyl salicylate may increase the hypoglycemic activities of Sulfadiazine. Approved, Vet Approved Methylene blue Methylene blue may increase the hypoglycemic activities of Sulfadiazine. Approved, Investigational Methylprednisolone The therapeutic efficacy of Sulfadiazine can be decreased when used in combination with Methylprednisolone. Approved, Vet Approved Methyltestosterone Methyltestosterone may increase the hypoglycemic activities of Sulfadiazine. Approved Metronidazole The metabolism of Metronidazole can be decreased when combined with Sulfadiazine. Approved Mibefradil The metabolism of Sulfadiazine can be decreased when combined with Mibefradil. Investigational, Withdrawn Miconazole The metabolism of Sulfadiazine can be decreased when combined with Miconazole. Approved, Investigational, Vet Approved Midostaurin The metabolism of Sulfadiazine can be decreased when combined with Midostaurin. Approved, Investigational Mifepristone The serum concentration of Sulfadiazine can be increased when it is combined with Mifepristone. Approved, Investigational Miglitol Miglitol may increase the hypoglycemic activities of Sulfadiazine. Approved Miglustat Miglustat may increase the hypoglycemic activities of Sulfadiazine. Approved Milnacipran Milnacipran may increase the hypoglycemic activities of Sulfadiazine. Approved, Investigational Minaprine Minaprine may increase the hypoglycemic activities of Sulfadiazine. Approved Mirtazapine The metabolism of Mirtazapine can be decreased when combined with Sulfadiazine. Approved Mitiglinide Mitiglinide may increase the hypoglycemic activities of Sulfadiazine. Approved, Investigational Mitotane The serum concentration of Sulfadiazine can be decreased when it is combined with Mitotane. Approved Moclobemide The metabolism of Moclobemide can be decreased when combined with Sulfadiazine. Approved, Investigational Montelukast The metabolism of Montelukast can be decreased when combined with Sulfadiazine. Approved Moxifloxacin The therapeutic efficacy of Sulfadiazine can be increased when used in combination with Moxifloxacin. Approved, Investigational Nabilone The metabolism of Sulfadiazine can be decreased when combined with Nabilone. Approved, Investigational Nabiximols The metabolism of Nabiximols can be decreased when combined with Sulfadiazine. Approved, Investigational Nalidixic Acid Nalidixic Acid may increase the hypoglycemic activities of Sulfadiazine. Approved, Investigational Nandrolone Nandrolone may increase the hypoglycemic activities of Sulfadiazine. Experimental, Investigational Nandrolone decanoate Nandrolone decanoate may increase the hypoglycemic activities of Sulfadiazine. Approved, Illicit Nateglinide The metabolism of Nateglinide can be decreased when combined with Sulfadiazine. Approved, Investigational Nefazodone The metabolism of Sulfadiazine can be decreased when combined with Nefazodone. Approved, Withdrawn Nelfinavir The metabolism of Sulfadiazine can be decreased when combined with Nelfinavir. Approved Nemonoxacin Nemonoxacin may increase the hypoglycemic activities of Sulfadiazine. Investigational Netupitant The serum concentration of Sulfadiazine can be increased when it is combined with Netupitant. Approved, Investigational Nevirapine The metabolism of Sulfadiazine can be increased when combined with Nevirapine. Approved Nialamide Nialamide may increase the hypoglycemic activities of Sulfadiazine. Withdrawn Nicardipine The metabolism of Sulfadiazine can be decreased when combined with Nicardipine. Approved, Investigational Niclosamide The metabolism of Niclosamide can be decreased when combined with Sulfadiazine. Approved, Investigational, Vet Approved Nicotine The risk or severity of adverse effects can be increased when Sulfadiazine is combined with Nicotine. Approved Nilotinib The metabolism of Sulfadiazine can be decreased when combined with Nilotinib. Approved, Investigational Nitric Oxide The risk or severity of adverse effects can be increased when Nitric Oxide is combined with Sulfadiazine. Approved Nitroaspirin Nitroaspirin may increase the hypoglycemic activities of Sulfadiazine. Investigational Nitrous acid The risk or severity of adverse effects can be increased when Sulfadiazine is combined with Nitrous acid. Approved, Investigational Norfloxacin Norfloxacin may increase the hypoglycemic activities of Sulfadiazine. Approved Nortriptyline The metabolism of Nortriptyline can be decreased when combined with Sulfadiazine. Approved Octamoxin Octamoxin may increase the hypoglycemic activities of Sulfadiazine. Withdrawn Octreotide Octreotide may increase the hypoglycemic activities of Sulfadiazine. Approved, Investigational Ofloxacin Ofloxacin may increase the hypoglycemic activities of Sulfadiazine. Approved Olaparib The metabolism of Sulfadiazine can be decreased when combined with Olaparib. Approved Olodaterol The metabolism of Olodaterol can be decreased when combined with Sulfadiazine. Approved Olsalazine Olsalazine may increase the hypoglycemic activities of Sulfadiazine. Approved Osimertinib The serum concentration of Sulfadiazine can be increased when it is combined with Osimertinib. Approved Ospemifene The serum concentration of Ospemifene can be increased when it is combined with Sulfadiazine. Approved, Investigational Oxandrolone Oxandrolone may increase the hypoglycemic activities of Sulfadiazine. Approved, Investigational Oxaprozin The metabolism of Oxaprozin can be decreased when combined with Sulfadiazine. Approved Oxolinic acid Oxolinic acid may increase the hypoglycemic activities of Sulfadiazine. Experimental Oxymetholone Oxymetholone may increase the hypoglycemic activities of Sulfadiazine. Approved, Illicit Paclitaxel The metabolism of Paclitaxel can be decreased when combined with Sulfadiazine. Approved, Vet Approved Palbociclib The serum concentration of Sulfadiazine can be increased when it is combined with Palbociclib. Approved, Investigational Paramethadione The metabolism of Paramethadione can be decreased when combined with Sulfadiazine. Approved Parecoxib The serum concentration of Parecoxib can be increased when it is combined with Sulfadiazine. Approved Pargyline Pargyline may increase the hypoglycemic activities of Sulfadiazine. Approved Paroxetine Paroxetine may increase the hypoglycemic activities of Sulfadiazine. Approved, Investigational Pasireotide Sulfadiazine may increase the hypoglycemic activities of Pasireotide. Approved Pazufloxacin Pazufloxacin may increase the hypoglycemic activities of Sulfadiazine. Investigational Pefloxacin Pefloxacin may increase the hypoglycemic activities of Sulfadiazine. Approved Pegvisomant Pegvisomant may increase the hypoglycemic activities of Sulfadiazine. Approved Pentamidine Sulfadiazine may increase the hypoglycemic activities of Pentamidine. Approved, Investigational Pentobarbital The metabolism of Sulfadiazine can be increased when combined with Pentobarbital. Approved, Investigational, Vet Approved Perphenazine The metabolism of Perphenazine can be decreased when combined with Sulfadiazine. Approved Phenacetin The metabolism of Phenacetin can be decreased when combined with Sulfadiazine. Withdrawn Phenelzine Phenelzine may increase the hypoglycemic activities of Sulfadiazine. Approved Phenformin Phenformin may increase the hypoglycemic activities of Sulfadiazine. Approved, Investigational, Withdrawn Phenindione Sulfadiazine may increase the anticoagulant activities of Phenindione. Approved, Investigational Pheniprazine Pheniprazine may increase the hypoglycemic activities of Sulfadiazine. Withdrawn Phenobarbital The metabolism of Sulfadiazine can be increased when combined with Phenobarbital. Approved, Investigational Phenoxypropazine Phenoxypropazine may increase the hypoglycemic activities of Sulfadiazine. Withdrawn Phenprocoumon The metabolism of Phenprocoumon can be decreased when combined with Sulfadiazine. Approved, Investigational Phenyl aminosalicylate Phenyl aminosalicylate may increase the hypoglycemic activities of Sulfadiazine. Approved Phenylbutazone The metabolism of Phenylbutazone can be decreased when combined with Sulfadiazine. Approved, Vet Approved Phenytoin The metabolism of Sulfadiazine can be increased when combined with Phenytoin. Approved, Vet Approved Pioglitazone The metabolism of Pioglitazone can be decreased when combined with Sulfadiazine. Approved, Investigational Pipemidic acid Pipemidic acid may increase the hypoglycemic activities of Sulfadiazine. Experimental Piperaquine The metabolism of Piperaquine can be decreased when combined with Sulfadiazine. Approved, Investigational Pirlindole Pirlindole may increase the hypoglycemic activities of Sulfadiazine. Approved Piromidic acid Piromidic acid may increase the hypoglycemic activities of Sulfadiazine. Experimental Piroxicam The metabolism of Piroxicam can be decreased when combined with Sulfadiazine. Approved, Investigational Pitavastatin The metabolism of Pitavastatin can be decreased when combined with Sulfadiazine. Approved Pitolisant The serum concentration of Sulfadiazine can be decreased when it is combined with Pitolisant. Approved, Investigational Pivhydrazine Pivhydrazine may increase the hypoglycemic activities of Sulfadiazine. Withdrawn Posaconazole The metabolism of Sulfadiazine can be decreased when combined with Posaconazole. Approved, Investigational, Vet Approved Pramlintide Pramlintide may increase the hypoglycemic activities of Sulfadiazine. Approved, Investigational Prasugrel The metabolism of Prasugrel can be decreased when combined with Sulfadiazine. Approved Pravastatin The metabolism of Pravastatin can be decreased when combined with Sulfadiazine. Approved Prednisolone The therapeutic efficacy of Sulfadiazine can be decreased when used in combination with Prednisolone. Approved, Vet Approved Pregabalin The risk or severity of heart failure can be increased when Pregabalin is combined with Sulfadiazine. Approved, Illicit, Investigational Prilocaine The risk or severity of adverse effects can be increased when Sulfadiazine is combined with Prilocaine. Approved Primidone The metabolism of Sulfadiazine can be increased when combined with Primidone. Approved, Vet Approved Procaine Procaine may increase the hypoglycemic activities of Sulfadiazine. Approved, Investigational, Vet Approved Procarbazine Procarbazine may increase the hypoglycemic activities of Sulfadiazine. Approved, Investigational Progesterone The metabolism of Progesterone can be decreased when combined with Sulfadiazine. Approved, Vet Approved Proguanil The metabolism of Proguanil can be decreased when combined with Sulfadiazine. Approved Promazine The metabolism of Promazine can be decreased when combined with Sulfadiazine. Approved, Vet Approved Propofol The metabolism of Propofol can be decreased when combined with Sulfadiazine. Approved, Investigational, Vet Approved Prulifloxacin Prulifloxacin may increase the hypoglycemic activities of Sulfadiazine. Investigational Pyrimethamine The metabolism of Sulfadiazine can be decreased when combined with Pyrimethamine. Approved, Investigational, Vet Approved Quazepam The metabolism of Quazepam can be decreased when combined with Sulfadiazine. Approved, Illicit Quetiapine The therapeutic efficacy of Sulfadiazine can be decreased when used in combination with Quetiapine. Approved Quinidine The metabolism of Quinidine can be decreased when combined with Sulfadiazine. Approved, Investigational Quinine The metabolism of Quinine can be decreased when combined with Sulfadiazine. Approved Rabeprazole The metabolism of Sulfadiazine can be decreased when combined with Rabeprazole. Approved, Investigational Ramelteon The serum concentration of Ramelteon can be increased when it is combined with Sulfadiazine. Approved, Investigational Ranolazine The metabolism of Sulfadiazine can be decreased when combined with Ranolazine. Approved, Investigational Rasagiline Rasagiline may increase the hypoglycemic activities of Sulfadiazine. Approved Repaglinide Sulfadiazine may increase the hypoglycemic activities of Repaglinide. Approved, Investigational Rifabutin The metabolism of Sulfadiazine can be increased when combined with Rifabutin. Approved, Investigational Rifampicin The metabolism of Sulfadiazine can be increased when combined with Rifampicin. Approved Rifapentine The metabolism of Sulfadiazine can be increased when combined with Rifapentine. Approved, Investigational Rofecoxib The metabolism of Rofecoxib can be decreased when combined with Sulfadiazine. Approved, Investigational, Withdrawn Rosiglitazone The therapeutic efficacy of Rosiglitazone can be increased when used in combination with Sulfadiazine. Approved, Investigational Rosoxacin Rosoxacin may increase the hypoglycemic activities of Sulfadiazine. Approved, Investigational Rosuvastatin The therapeutic efficacy of Sulfadiazine can be increased when used in combination with Rosuvastatin. Approved Rucaparib The metabolism of Sulfadiazine can be decreased when combined with Rucaparib. Approved, Investigational Rupatadine The metabolism of Rupatadine can be decreased when combined with Sulfadiazine. Approved Safrazine Safrazine may increase the hypoglycemic activities of Sulfadiazine. Withdrawn Salicylic acid Salicylic acid may increase the hypoglycemic activities of Sulfadiazine. Approved, Investigational, Vet Approved Saquinavir The metabolism of Sulfadiazine can be decreased when combined with Saquinavir. Approved, Investigational Sarilumab The therapeutic efficacy of Sulfadiazine can be decreased when used in combination with Sarilumab. Approved, Investigational Saxagliptin The therapeutic efficacy of Saxagliptin can be increased when used in combination with Sulfadiazine. Approved Secobarbital The metabolism of Sulfadiazine can be increased when combined with Secobarbital. Approved, Vet Approved Selegiline The metabolism of Selegiline can be decreased when combined with Sulfadiazine. Approved, Investigational, Vet Approved Seratrodast The metabolism of Seratrodast can be decreased when combined with Sulfadiazine. Approved Sertraline The metabolism of Sertraline can be decreased when combined with Sulfadiazine. Approved Sildenafil The metabolism of Sildenafil can be decreased when combined with Sulfadiazine. Approved, Investigational Siltuximab The serum concentration of Sulfadiazine can be decreased when it is combined with Siltuximab. Approved, Investigational Silver sulfadiazine The therapeutic efficacy of Sulfadiazine can be increased when used in combination with Silver sulfadiazine. Approved, Vet Approved Simeprevir The serum concentration of Sulfadiazine can be increased when it is combined with Simeprevir. Approved Sitafloxacin Sitafloxacin may increase the hypoglycemic activities of Sulfadiazine. Experimental, Investigational Sitagliptin The therapeutic efficacy of Sitagliptin can be increased when used in combination with Sulfadiazine. Approved, Investigational Sitaxentan The metabolism of Sitaxentan can be decreased when combined with Sulfadiazine. Approved, Investigational, Withdrawn Sorafenib The metabolism of Sulfadiazine can be decreased when combined with Sorafenib. Approved, Investigational Sotagliflozin Sotagliflozin may increase the hypoglycemic activities of Sulfadiazine. Investigational Sparfloxacin Sparfloxacin may increase the hypoglycemic activities of Sulfadiazine. Approved, Investigational St. John's Wort The serum concentration of Sulfadiazine can be decreased when it is combined with St. John's Wort. Approved, Investigational, Nutraceutical Stanolone Stanolone may increase the hypoglycemic activities of Sulfadiazine. Illicit, Investigational Stanozolol Stanozolol may increase the hypoglycemic activities of Sulfadiazine. Approved, Vet Approved Stiripentol The serum concentration of Sulfadiazine can be increased when it is combined with Stiripentol. Approved Sulfamethoxazole The metabolism of Sulfamethoxazole can be decreased when combined with Sulfadiazine. Approved Sulfamoxole The metabolism of Sulfamoxole can be decreased when combined with Sulfadiazine. Approved Sulfasalazine Sulfasalazine may increase the hypoglycemic activities of Sulfadiazine. Approved Sulfinpyrazone The metabolism of Sulfinpyrazone can be decreased when combined with Sulfadiazine. Approved Sulfisoxazole The metabolism of Sulfisoxazole can be decreased when combined with Sulfadiazine. Approved, Vet Approved Sulodexide Sulodexide may increase the hypoglycemic activities of Sulfadiazine. Approved, Investigational Sumatriptan The therapeutic efficacy of Sulfadiazine can be increased when used in combination with Sumatriptan. Approved, Investigational Sunitinib Sulfadiazine may increase the hypoglycemic activities of Sunitinib. Approved, Investigational Suprofen The metabolism of Suprofen can be decreased when combined with Sulfadiazine. Approved, Withdrawn Tamoxifen The metabolism of Tamoxifen can be decreased when combined with Sulfadiazine. Approved Tapentadol The metabolism of Tapentadol can be decreased when combined with Sulfadiazine. Approved Telaprevir The metabolism of Sulfadiazine can be decreased when combined with Telaprevir. Approved, Withdrawn Telithromycin The metabolism of Sulfadiazine can be decreased when combined with Telithromycin. Approved Temafloxacin Temafloxacin may increase the hypoglycemic activities of Sulfadiazine. Withdrawn Temazepam The metabolism of Temazepam can be decreased when combined with Sulfadiazine. Approved, Investigational Tenoxicam The metabolism of Tenoxicam can be decreased when combined with Sulfadiazine. Approved Terfenadine The metabolism of Terfenadine can be decreased when combined with Sulfadiazine. Approved, Withdrawn Teriflunomide The metabolism of Sulfadiazine can be decreased when combined with Teriflunomide. Approved Testosterone The metabolism of Testosterone can be decreased when combined with Sulfadiazine. Approved, Investigational Testosterone cypionate The metabolism of Testosterone cypionate can be decreased when combined with Sulfadiazine. Approved Testosterone enanthate The metabolism of Testosterone enanthate can be decreased when combined with Sulfadiazine. Approved Testosterone propionate Testosterone propionate may increase the hypoglycemic activities of Sulfadiazine. Approved, Investigational, Vet Approved, Withdrawn Testosterone undecanoate The metabolism of Testosterone undecanoate can be decreased when combined with Sulfadiazine. Approved, Investigational Thalidomide The metabolism of Thalidomide can be decreased when combined with Sulfadiazine. Approved, Investigational, Withdrawn Theophylline The metabolism of Theophylline can be decreased when combined with Sulfadiazine. Approved Thiamylal The metabolism of Thiamylal can be decreased when combined with Sulfadiazine. Approved, Vet Approved Ticagrelor The metabolism of Sulfadiazine can be decreased when combined with Ticagrelor. Approved Ticlopidine The metabolism of Sulfadiazine can be decreased when combined with Ticlopidine. Approved Tioclomarol Sulfadiazine may increase the anticoagulant activities of Tioclomarol. Experimental Tocilizumab The serum concentration of Sulfadiazine can be decreased when it is combined with Tocilizumab. Approved Tolazamide Sulfadiazine may increase the hypoglycemic activities of Tolazamide. Approved, Investigational Tolbutamide The metabolism of Sulfadiazine can be decreased when combined with Tolbutamide. Approved, Investigational Toloxatone Toloxatone may increase the hypoglycemic activities of Sulfadiazine. Approved Tolterodine The metabolism of Tolterodine can be decreased when combined with Sulfadiazine. Approved, Investigational Topiroxostat The metabolism of Sulfadiazine can be decreased when combined with Topiroxostat. Approved, Investigational Torasemide The metabolism of Torasemide can be decreased when combined with Sulfadiazine. Approved Trabectedin The metabolism of Trabectedin can be decreased when combined with Sulfadiazine. Approved, Investigational Tranylcypromine Tranylcypromine may increase the hypoglycemic activities of Sulfadiazine. Approved, Investigational Treprostinil The metabolism of Treprostinil can be decreased when combined with Sulfadiazine. Approved, Investigational Tretinoin The metabolism of Tretinoin can be decreased when combined with Sulfadiazine. Approved, Investigational, Nutraceutical Trimethoprim The metabolism of Trimethoprim can be decreased when combined with Sulfadiazine. Approved, Vet Approved Trimipramine The metabolism of Trimipramine can be decreased when combined with Sulfadiazine. Approved Troglitazone The metabolism of Troglitazone can be decreased when combined with Sulfadiazine. Investigational, Withdrawn Trolamine salicylate Trolamine salicylate may increase the hypoglycemic activities of Sulfadiazine. Approved Trovafloxacin Trovafloxacin may increase the hypoglycemic activities of Sulfadiazine. Approved, Investigational, Withdrawn Valdecoxib The metabolism of Valdecoxib can be decreased when combined with Sulfadiazine. Approved, Investigational, Withdrawn Valsartan The metabolism of Valsartan can be decreased when combined with Sulfadiazine. Approved, Investigational Vemurafenib The serum concentration of Sulfadiazine can be decreased when it is combined with Vemurafenib. Approved Venlafaxine Venlafaxine may increase the hypoglycemic activities of Sulfadiazine. Approved Verapamil The metabolism of Sulfadiazine can be decreased when combined with Verapamil. Approved Vicriviroc The metabolism of Vicriviroc can be decreased when combined with Sulfadiazine. Investigational Vildagliptin Vildagliptin may increase the hypoglycemic activities of Sulfadiazine. Approved, Investigational Vismodegib The metabolism of Vismodegib can be decreased when combined with Sulfadiazine. Approved, Investigational Voglibose Voglibose may increase the hypoglycemic activities of Sulfadiazine. Approved, Investigational Voriconazole The metabolism of Sulfadiazine can be decreased when combined with Voriconazole. Approved, Investigational Vortioxetine The metabolism of Vortioxetine can be decreased when combined with Sulfadiazine. Approved, Investigational Warfarin The metabolism of Warfarin can be decreased when combined with Sulfadiazine. Approved Ximelagatran The metabolism of Ximelagatran can be decreased when combined with Sulfadiazine. Approved, Investigational, Withdrawn Zafirlukast The metabolism of Zafirlukast can be decreased when combined with Sulfadiazine. Approved, Investigational Zalcitabine The metabolism of Zalcitabine can be decreased when combined with Sulfadiazine. Approved, Investigational Zaltoprofen The metabolism of Zaltoprofen can be decreased when combined with Sulfadiazine. Approved, Investigational Zileuton The metabolism of Zileuton can be decreased when combined with Sulfadiazine. Approved, Investigational, Withdrawn Zimelidine Zimelidine may increase the hypoglycemic activities of Sulfadiazine. Withdrawn Ziprasidone The metabolism of Sulfadiazine can be decreased when combined with Ziprasidone. Approved Zopiclone The metabolism of Zopiclone can be decreased when combined with Sulfadiazine. Approved - Food Interactions
- Not Available
References
- Synthesis Reference
Charles L. Fox, Jr., Shanta M. Modak, Paul Fox, "Wound dressing comprising silver sulfadiazine incorporated in animal tissue and method of preparation." U.S. Patent US4599226, issued September, 1977.
US4599226- General References
- Not Available
- External Links
- Human Metabolome Database
- HMDB0014503
- KEGG Drug
- D00587
- KEGG Compound
- C07658
- PubChem Compound
- 5215
- PubChem Substance
- 46506164
- ChemSpider
- 5026
- BindingDB
- 50166571
- ChEBI
- 9328
- ChEMBL
- CHEMBL439
- Therapeutic Targets Database
- DAP001238
- PharmGKB
- PA451539
- Drugs.com
- Drugs.com Drug Page
- Wikipedia
- Sulfadiazine
- ATC Codes
- J01EE06 — Sulfadiazine and tetroxoprim
- J01EE — Combinations of sulfonamides and trimethoprim, incl. derivatives
- J01E — SULFONAMIDES AND TRIMETHOPRIM
- J01 — ANTIBACTERIALS FOR SYSTEMIC USE
- J — ANTIINFECTIVES FOR SYSTEMIC USE
- J01EE — Combinations of sulfonamides and trimethoprim, incl. derivatives
- J01E — SULFONAMIDES AND TRIMETHOPRIM
- J01 — ANTIBACTERIALS FOR SYSTEMIC USE
- J — ANTIINFECTIVES FOR SYSTEMIC USE
- J01EC — Intermediate-acting sulfonamides
- J01E — SULFONAMIDES AND TRIMETHOPRIM
- J01 — ANTIBACTERIALS FOR SYSTEMIC USE
- J — ANTIINFECTIVES FOR SYSTEMIC USE
- MSDS
- Download (73.5 KB)
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 0 Recruiting Treatment Osteomyelitis 1 2 Completed Treatment Human Immunodeficiency Virus (HIV) Infections / Toxoplasmosis, Cerebral 1 2 Completed Treatment Minor burns 1 3 Completed Treatment Toxoplasmosis, Congenital 1 4 Recruiting Treatment Toxoplasmosis 1
Pharmacoeconomics
- Manufacturers
- Abbott laboratories pharmaceutical products div
- Everylife
- Impax laboratories inc
- Lannett co inc
- Lederle laboratories div american cyanamid co
- Eli lilly and co
- Sandoz inc
- Packagers
- Amend
- A-S Medication Solutions LLC
- C.O. Truxton Inc.
- Eon Labs
- Kaiser Foundation Hospital
- Murfreesboro Pharmaceutical Nursing Supply
- Qualitest
- Dosage forms
Form Route Strength Suspension Oral Tablet Oral Suppository Vaginal Cream Vaginal Tablet Oral 500 mg/1 Tablet Oral 500.5 mg - Prices
Unit description Cost Unit Silver Sulfadiazine 1% Cream 400 gm Jar 36.48USD jar Silver Sulfadiazine 1% Cream 50 gm Jar 21.99USD jar Silver Sulfadiazine 1% Cream 85 gm Jar 19.99USD jar Silver Sulfadiazine 1% Cream 25 gm Jar 13.99USD jar Sulfadiazine 500 mg tablet 2.5USD tablet Sulfazine EC 500 mg Enteric Coated Tabs 0.42USD tab Sulfazine ec 500 mg tablet 0.38USD tablet Sulfazine 500 mg tablet 0.25USD tablet Sulfadiazine powder 0.13USD g DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
Property Value Source melting point (°C) 255.5 dec °C PhysProp water solubility 77 mg/L (at 25 °C) YALKOWSKY,SH & DANNENFELSER,RM (1992) logP -0.09 HANSCH,C ET AL. (1995) logS -3.51 ADME Research, USCD pKa 6.36 SANGSTER (1994) - Predicted Properties
Property Value Source Water Solubility 0.601 mg/mL ALOGPS logP 0.25 ALOGPS logP 0.39 ChemAxon logS -2.6 ALOGPS pKa (Strongest Acidic) 6.99 ChemAxon pKa (Strongest Basic) 2.01 ChemAxon Physiological Charge -1 ChemAxon Hydrogen Acceptor Count 5 ChemAxon Hydrogen Donor Count 2 ChemAxon Polar Surface Area 97.97 Å2 ChemAxon Rotatable Bond Count 2 ChemAxon Refractivity 64.2 m3·mol-1 ChemAxon Polarizability 24.39 Å3 ChemAxon Number of Rings 2 ChemAxon Bioavailability 1 ChemAxon Rule of Five Yes ChemAxon Ghose Filter Yes ChemAxon Veber's Rule No ChemAxon MDDR-like Rule No ChemAxon - Predicted ADMET features
Property Value Probability Human Intestinal Absorption + 0.9877 Blood Brain Barrier + 0.9383 Caco-2 permeable + 0.6988 P-glycoprotein substrate Non-substrate 0.9012 P-glycoprotein inhibitor I Non-inhibitor 0.913 P-glycoprotein inhibitor II Non-inhibitor 0.9156 Renal organic cation transporter Non-inhibitor 0.8437 CYP450 2C9 substrate Non-substrate 0.8031 CYP450 2D6 substrate Non-substrate 0.915 CYP450 3A4 substrate Non-substrate 0.7671 CYP450 1A2 substrate Non-inhibitor 0.9574 CYP450 2C9 inhibitor Non-inhibitor 0.922 CYP450 2D6 inhibitor Non-inhibitor 0.9548 CYP450 2C19 inhibitor Non-inhibitor 0.9693 CYP450 3A4 inhibitor Non-inhibitor 0.902 CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.8569 Ames test Non AMES toxic 0.9206 Carcinogenicity Non-carcinogens 0.9393 Biodegradation Not ready biodegradable 0.9973 Rat acute toxicity 1.8353 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.9383 hERG inhibition (predictor II) Non-inhibitor 0.8673
Spectra
- Mass Spec (NIST)
- Download (7.99 KB)
- Spectra
Taxonomy
- Description
- This compound belongs to the class of organic compounds known as aminobenzenesulfonamides. These are organic compounds containing a benzenesulfonamide moiety with an amine group attached to the benzene ring.
- Kingdom
- Organic compounds
- Super Class
- Benzenoids
- Class
- Benzene and substituted derivatives
- Sub Class
- Benzenesulfonamides
- Direct Parent
- Aminobenzenesulfonamides
- Alternative Parents
- Benzenesulfonyl compounds / Aniline and substituted anilines / Pyrimidines and pyrimidine derivatives / Organosulfonamides / Heteroaromatic compounds / Aminosulfonyl compounds / Azacyclic compounds / Primary amines / Organopnictogen compounds / Organic oxides show 1 more
- Substituents
- Aminobenzenesulfonamide / Benzenesulfonyl group / Aniline or substituted anilines / Pyrimidine / Organosulfonic acid amide / Organic sulfonic acid or derivatives / Organosulfonic acid or derivatives / Heteroaromatic compound / Aminosulfonyl compound / Sulfonyl show 12 more
- Molecular Framework
- Aromatic heteromonocyclic compounds
- External Descriptors
- substituted aniline, sulfonamide, pyrimidines, sulfonamide antibiotic (CHEBI:9328)
Targets
- Kind
- Protein
- Organism
- Plasmodium falciparum
- Pharmacological action
- Yes
- Actions
- Inhibitor
- General Function
- Dihydropteroate synthase activity
- Specific Function
- Not Available
- Gene Name
- Not Available
- Uniprot ID
- Q27738
- Uniprot Name
- Dihydropteroate synthetase
- Molecular Weight
- 43370.845 Da
References
- de Araujo MV, Vieira EK, Silva Lazaro G, Conegero LS, Almeida LE, Barreto LS, da Costa NB Jr, Gimenez IF: Sulfadiazine/hydroxypropyl-beta-cyclodextrin host-guest system: Characterization, phase-solubility and molecular modeling. Bioorg Med Chem. 2008 May 15;16(10):5788-94. doi: 10.1016/j.bmc.2008.03.057. Epub 2008 Mar 27. [PubMed:18434167]
- Iliades P, Meshnick SR, Macreadie IG: Mutations in the Pneumocystis jirovecii DHPS gene confer cross-resistance to sulfa drugs. Antimicrob Agents Chemother. 2005 Feb;49(2):741-8. [PubMed:15673759]
- Prabhu V, Lui H, King J: Arabidopsis dihydropteroate synthase: general properties and inhibition by reaction product and sulfonamides. Phytochemistry. 1997 May;45(1):23-7. [PubMed:9127492]
Enzymes
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- General Function
- Steroid hydroxylase activity
- Specific Function
- Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
- Gene Name
- CYP2C9
- Uniprot ID
- P11712
- Uniprot Name
- Cytochrome P450 2C9
- Molecular Weight
- 55627.365 Da
References
- Komatsu K, Ito K, Nakajima Y, Kanamitsu Si, Imaoka S, Funae Y, Green CE, Tyson CA, Shimada N, Sugiyama Y: Prediction of in vivo drug-drug interactions between tolbutamide and various sulfonamides in humans based on in vitro experiments. Drug Metab Dispos. 2000 Apr;28(4):475-81. [PubMed:10725317]
- Winter HR, Unadkat JD: Identification of cytochrome P450 and arylamine N-acetyltransferase isoforms involved in sulfadiazine metabolism. Drug Metab Dispos. 2005 Jul;33(7):969-76. doi: 10.1124/dmd.104.002998. Epub 2005 Apr 20. [PubMed:15843491]
- Clin-Info. (2006). In Compendium of Pharmaceuticals and Specialties: The Canadian Drug Reference for Health Professionals (pp. L58). Canadian Pharmacists Association. [ISBN:1-894402-22-7]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Substrate
- General Function
- Steroid hydroxylase activity
- Specific Function
- Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
- Gene Name
- CYP2C8
- Uniprot ID
- P10632
- Uniprot Name
- Cytochrome P450 2C8
- Molecular Weight
- 55824.275 Da
References
- Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Substrate
- General Function
- Steroid hydroxylase activity
- Specific Function
- Metabolizes several precarcinogens, drugs, and solvents to reactive metabolites. Inactivates a number of drugs and xenobiotics and also bioactivates many xenobiotic substrates to their hepatotoxic ...
- Gene Name
- CYP2E1
- Uniprot ID
- P05181
- Uniprot Name
- Cytochrome P450 2E1
- Molecular Weight
- 56848.42 Da
References
- Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Substrate
- General Function
- Vitamin d3 25-hydroxylase activity
- Specific Function
- Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
- Gene Name
- CYP3A4
- Uniprot ID
- P08684
- Uniprot Name
- Cytochrome P450 3A4
- Molecular Weight
- 57342.67 Da
References
- Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Drug created on June 13, 2005 07:24 / Updated on August 02, 2018 07:53